IRLAB Therapeutics AB (publ) Total Assets
IRLAB Therapeutics AB (publ) total assets. Based on the latest financial reports, IRLAB Therapeutics AB (publ) (IRLAB-A) holds total assets worth Skr138.21 Million SEK (≈ $14.87 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see IRLAB Therapeutics AB (publ) market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of IRLAB Therapeutics AB (publ) (2013–2025)
Total assets of IRLAB Therapeutics AB (publ) from 2013 to 2025. This chart illustrates how IRLAB Therapeutics AB (publ)'s total assets have evolved over time, based on quarterly financial data. See IRLAB Therapeutics AB (publ) share price for real-time trading data and today's change.
IRLAB Therapeutics AB (publ) - Asset Composition Analysis
IRLAB Therapeutics AB (publ) Total Assets Breakdown (December 2025)
IRLAB Therapeutics AB (publ) total assets breakdown as of December 2025. IRLAB Therapeutics AB (publ)'s total assets of Skr138.21 Million consist of 62.1% current assets and 37.9% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr81.86 Million | 59.2% |
| Accounts Receivable | Skr4.01 Million | 2.9% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr5.47 Million | 4.0% |
| Intangible Assets | Skr46.86 Million | 33.9% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how IRLAB Therapeutics AB (publ)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore IRLAB-A working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: IRLAB Therapeutics AB (publ)'s current assets represent 62.1% of total assets in 2025, an increase from 0.0% in 2013.
- Cash Position: Cash and equivalents constituted 59.2% of total assets in 2025, up from 0.0% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 33.0% of total assets, an increase from 0.0% in 2013.
- Asset Diversification: The largest asset category is cash and equivalents at 59.2% of total assets.
IRLAB Therapeutics AB (publ) Competitors by Total Assets
Key competitors of IRLAB Therapeutics AB (publ) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
IRLAB Therapeutics AB (publ) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.80 | 0.80 | 13.98 |
| Quick Ratio | 0.80 | 0.80 | 13.98 |
| Cash Ratio | 0.76 | 0.67 | 0.00 |
| Working Capital | Skr-21.62 Million | Skr-20.48 Million | Skr241.41 Million |
IRLAB Therapeutics AB (publ) - Advanced Valuation Insights
This section examines the relationship between IRLAB Therapeutics AB (publ)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.48 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | 1.5% |
| Total Assets | Skr138.21 Million |
| Market Capitalization | $18.49 Million USD |
Valuation Analysis
Below Book Valuation: The market values IRLAB Therapeutics AB (publ)'s assets below their book value (0.13x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: IRLAB Therapeutics AB (publ)'s assets grew by 1.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for IRLAB Therapeutics AB (publ) (2013–2025)
The table below shows the annual total assets of IRLAB Therapeutics AB (publ) from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr138.21 Million ≈ $14.87 Million |
+1.47% |
| 2024-12-31 | Skr136.21 Million ≈ $14.66 Million |
-23.10% |
| 2023-12-31 | Skr177.12 Million ≈ $19.06 Million |
-45.26% |
| 2022-12-31 | Skr323.56 Million ≈ $34.82 Million |
-31.52% |
| 2021-12-31 | Skr472.45 Million ≈ $50.84 Million |
+27.67% |
| 2020-12-31 | Skr370.07 Million ≈ $39.83 Million |
+77.86% |
| 2019-12-31 | Skr208.07 Million ≈ $22.39 Million |
-7.50% |
| 2018-12-31 | Skr224.94 Million ≈ $24.21 Million |
+38.02% |
| 2017-12-31 | Skr162.97 Million ≈ $17.54 Million |
+44.08% |
| 2016-12-31 | Skr113.11 Million ≈ $12.17 Million |
+11.89% |
| 2015-12-31 | Skr101.09 Million ≈ $10.88 Million |
-5.01% |
| 2014-12-31 | Skr106.43 Million ≈ $11.45 Million |
+325.73% |
| 2013-12-31 | Skr25.00 Million ≈ $2.69 Million |
-- |
About IRLAB Therapeutics AB (publ)
IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson's disease and other central nervous system (CNS) disorders in the United States. The company develops Mesdopetam (IRL790), which has completed both a Phase IIb clinical trial for the treatment of levodopa-induced dyskinesias, and a Phase I clinical trial for the treatment of Parkinson's disease psychosis; Pir… Read more